Spyre Therapeutics (SYRE) Retained Earnings (2015 - 2026)
Spyre Therapeutics (SYRE) posted Retained Earnings of -$1.2 billion for Q1 2026, down 6.42% on a QoQ basis from -$1.1 billion in Q4 2025, and down 17.97% year-over-year from -$1.5 billion in Q1 2025.
Spyre Therapeutics (SYRE) Retained Earnings (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Retained Earnings history runs 12 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.
- Quarterly Retained Earnings fell 17.97% year-over-year to -$1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 17.97% YoY) and the FY2025 annual result came in at -$1.1 billion, down 626563.89% from the prior year.
- Retained Earnings was -$1.2 billion for Q1 2026 at Spyre Therapeutics, down from -$1.1 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $302000.0 in Q4 2023 and bottomed at -$1.2 billion in Q1 2026.
- A 5-year average of -$651.1 million and a median of -$701.2 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings slumped 2128020.0% — and 2023, when it soared 100.07%.
- Spyre Therapeutics' Retained Earnings stood at -$425.6 million in 2022, then surged by 100.07% to $302000.0 in 2023, then tumbled by 40.4% to $180000.0 in 2024, then tumbled by 626563.89% to -$1.1 billion in 2025, then declined by 6.42% to -$1.2 billion in 2026.
- Business Quant data shows SYRE's Retained Earnings at -$1.2 billion in Q1 2026, -$1.1 billion in Q4 2025, and -$1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.20 Bn |
| Dec 31, 2025 | -1.13 Bn |
| Sep 30, 2025 | -1.07 Bn |
| Jun 30, 2025 | -1.10 Bn |
| Mar 31, 2025 | -1.02 Bn |
| Dec 31, 2024 | 180,000.00 |
| Sep 30, 2024 | -916.14 Mn |
| Jun 30, 2024 | -847.11 Mn |
| Mar 31, 2024 | -808.27 Mn |
| Dec 31, 2023 | 302,000.00 |
| Sep 30, 2023 | -701.20 Mn |
| Jun 30, 2023 | -661.10 Mn |
| Mar 31, 2023 | -444.05 Mn |
| Dec 31, 2022 | -425.62 Mn |
| Sep 30, 2022 | -184,000.00 |
| Jun 30, 2022 | -388.57 Mn |
| Mar 31, 2022 | -366.25 Mn |
| Dec 31, 2021 | -20,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | -301.10 Mn |